1201 Camino de Salud, NE MSC07 4025 UNMCC Administration Building, Albuquerque, NM 87131
Website: University of New Mexico Comprehensive Cancer Center
Contact:
Rebecca Myers-Brito
505-925-0355
1201 Camino de Salud, NE MSC07 4025 UNMCC Administration Building, Albuquerque, NM 87131
Website: University of New Mexico Comprehensive Cancer Center
Contact:
Rebecca Myers-Brito
505-925-0355
A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer: HCRN GU14-182
Status: Closed to Accrual
Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
Status: Closed to Accrual
A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma
Status: Closed to Accrual
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter